Paper

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

Published Oct 1, 2004 · F. Debruyne, J. Barkin, Peter van Erps

European urology

218

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCTHighly Cited

Study Snapshot

Long-term dutasteride treatment improves urinary symptoms, flow rate, and reduces prostate volume in men with symptomatic benign prostatic hyperplasia, while maintaining a low risk of acute urinary retention and BPH-related surgery.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.

References

Citations